Dr. Ron Vender
Dr. Ron Vender is a Dermatologist who currently practices in Hamilton. He is the founder and director of Dermatrials Research Incorporated and Venderm Innovations in Psoriasis.
He has participated as principal investigator in over 100 clinical trials. He is Associate Clinical Professor at McMaster University in the Department of Medicine, Division of Dermatology. He is Honorary Staff at St. Joseph’s Healthcare in Hamilton ON. Dr. Vender serves on the editorial board of the Journal of Cutaneous Medicine and Surgery reviewer for the JEADV, JAAD, and BJD. He is one of eight Canadians elected to the International Psoriasis Council, a member of the Canadian Professors of Dermatology and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis.
He represents Canada on several Global educational steering committees as well as international advisory boards. He has published many peer-reviewed manuscripts and has had posters, abstracts and lectures presented internationally.
Friday NOV 12, 2021
Treating moderate-to-severe plaque psoriasis to target: new and old concepts for topical and biologic therapies
Treat-to-target (T2T) refers to a clinical framework for managing chronic diseases that sets standards for assessing treatment goals and suggests treatment strategies if targets are not achieved. T2T recommendations in moderate-to-severe plaque psoriasis have been published by expert groups from around the world. In these, treatment target is usually defined by a single severity measure, targets vary between consensus groups, and there are few recommendations for modifying treatment if target is not achieved. In this symposium, we present a multi-dimensional, criteria-based, T2T model developed by Canadian dermatologists managing moderate-to-severe plaque psoriasis. Treatment modification strategies will be presented and discussed with a focus on optimizing or switching biologic treatments. As topical treatments as mainstays in managing psoriasis, their role within a T2T model will be discussed with consideration given to long-term data from recently published studies.
- Introduce a Canadian criteria-based model for treatment targets in plaque psoriasis.
- Review evidence supporting treatment strategies for when target is not achieved, with a focus on switching biologics.
- Consider a treat-to-target approach in the early management of plaque psoriasis and critically appraise new clinical data on the long-term management of plaque psoriasis using topical treatments
Saturday NOV 13, 2021
A Sneak Peek at Bimekizumab: A Review of the Data
Dr. Ron Vender and Dr. Kerri Purdy will examine the efficacy and safety of bimekizumab in patients with moderate to severe psoriasis. At the conclusion of this session, physicians will be informed about: bimekizumab's clinical trial efficacy and safety data in patients with moderate to severe psoriasis; and Canadian investigators' first-hand experience with bimekizumab in patients with moderate to severe psoriasis.